LIGAND PHARMACEUTICALS INC (LGND) Form 8-K — Jul 14, 2026

$LGNDForm 8-KItems 1.01, 2.01, 2.03, 7.01, 9.01Filed Jul 14, 2026, 9:20 AM ET0001193125-26-302660Original filing

Ligand Pharmaceuticals Incorporated completed its acquisition of XOMA Royalty Corporation for $39.00 per share in cash, representing a total equity value of approximately $739 million. The transaction adds seven commercial products, including Roche's VABYSMO and Servier's OJEMDA, doubling Ligand's portfolio to over 200 royalty assets. In connection with the closing, Ligand entered into an Amended and Restated Credit Agreement providing a $125.0 million revolving credit facility maturing September 12, 2028. The company expects the acquisition to be immediately accretive, adding approximately $0.50 and $1.50 to projected adjusted earnings per share for 2026 and 2027, respectively.

Key figures

Debt Amount: 125000000
Deal Value Usd: 739000000
Eps Accretion2026: $0.50
Eps Accretion2027: $1.50
Total Equity Value: $739 million
Purchase Price Per Share: 39
Credit Facility Maturity: September 12, 2028

Price after filing

1 day: -1.6%7 days: +1.5%30 days: -2.6%

Close on the filing date to close N calendar days later (from $300.97). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.